Literature DB >> 17604632

Malondialdehyde scavenging and aldose-derived Schiff bases' transglycation properties of synthetic histidyl-hydrazide carnosine analogs.

Andrea Guiotto1, Paolo Ruzza, Mark A Babizhayev, Andrea Calderan.   

Abstract

Second-generation carnosine analogs bearing the histidyl-hydrazide moiety have been synthesized and tested for their efficiency in scavenging malondialdehyde (MDA) derived from lipid peroxidation and for their ability to reverse the glycation process in the glucose-ethylamine Schiff base model. The data obtained indicate that this class of compounds maintains the activity profile of carnosine and is a suitable candidate for the treatment of disorders caused by oxidative stress.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17604632     DOI： 10.1016/j.bmc.2007.06.029

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN： 0968-0896            Impact factor:   3.641


  4 in total

1.  Plasma metabolic profile delineates roles for neurodegeneration, pro-inflammatory damage and mitochondrial dysfunction in the FMR1 premutation.

Authors:  Cecilia Giulivi; Eleonora Napoli; Flora Tassone; Julian Halmai; Randi Hagerman
Journal:  Biochem J       Date:  2016-08-23       Impact factor: 3.857

Review 2.  Diabetes and Pancreatic Cancer-A Dangerous Liaison Relying on Carbonyl Stress.

Authors:  Stefano Menini; Carla Iacobini; Martina Vitale; Carlo Pesce; Giuseppe Pugliese
Journal:  Cancers (Basel)       Date:  2021-01-16       Impact factor: 6.639

3.  Oxidative Stress and Free Radical Processes in Tumor and Non-Tumor Obstructive Jaundice: Influence of Disease Duration, Severity and Surgical Treatment on Outcomes.

Authors:  Ekaterina Vladimirovna Silina; Victor Alexandrovich Stupin; Igor Sergeevich Abramov; Sergey Brankovich Bolevich; Gouri Deshpande; Raghu Ram Achar; Tatiana Georgievna Sinelnikova
Journal:  Pathophysiology       Date:  2022-01-31

4.  N-Acetylcarnosine sustained drug delivery eye drops to control the signs of ageless vision: glare sensitivity, cataract amelioration and quality of vision currently available treatment for the challenging 50,000-patient population.

Authors:  Mark A Babizhayev; Leslie Burke; Philip Micans; Stuart P Richer
Journal:  Clin Interv Aging       Date:  2009-05-14       Impact factor: 4.458
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.